(NASDAQ: PSTV) Plus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Plus Therapeutics's earnings in 2025 is -$27,118,000.On average, 1 Wall Street analyst forecast PSTV's earnings for 2025 to be -$11,123,798, with the lowest PSTV earnings forecast at -$11,123,798, and the highest PSTV earnings forecast at -$11,123,798. On average, 2 Wall Street analysts forecast PSTV's earnings for 2026 to be -$18,648,721, with the lowest PSTV earnings forecast at -$19,957,403, and the highest PSTV earnings forecast at -$17,340,039.
In 2027, PSTV is forecast to generate -$16,031,356 in earnings, with the lowest earnings forecast at -$16,031,356 and the highest earnings forecast at -$16,031,356.